PL442316A1 - Kompozycja farmaceutyczna do stosowania miejscowego oraz jej zastosowanie w leczeniu naczyniaków krwionośnych u dzieci - Google Patents

Kompozycja farmaceutyczna do stosowania miejscowego oraz jej zastosowanie w leczeniu naczyniaków krwionośnych u dzieci

Info

Publication number
PL442316A1
PL442316A1 PL442316A PL44231622A PL442316A1 PL 442316 A1 PL442316 A1 PL 442316A1 PL 442316 A PL442316 A PL 442316A PL 44231622 A PL44231622 A PL 44231622A PL 442316 A1 PL442316 A1 PL 442316A1
Authority
PL
Poland
Prior art keywords
hemangiomas
children
treatment
pharmaceutical composition
topical
Prior art date
Application number
PL442316A
Other languages
English (en)
Other versions
PL244294B1 (pl
Inventor
Jerzy Niedzielski
Paweł Szymański
Kamila Czarnecka
Original Assignee
Uniwersytet Medyczny w Łodzi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny w Łodzi filed Critical Uniwersytet Medyczny w Łodzi
Priority to PL442316A priority Critical patent/PL244294B1/pl
Publication of PL442316A1 publication Critical patent/PL442316A1/pl
Priority to PCT/PL2023/050078 priority patent/WO2024063661A1/en
Priority to EP23818563.1A priority patent/EP4590288A1/en
Publication of PL244294B1 publication Critical patent/PL244294B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia jest kompozycja farmaceutyczna do stosowania miejscowego zawierająca antagonistę receptorów beta-adrenergicznych i kortykosteroid oraz jej zastosowanie w leczeniu naczyniaków krwionośnych u dzieci.
PL442316A 2022-09-20 2022-09-20 Kompozycja farmaceutyczna do stosowania miejscowego oraz jej zastosowanie w leczeniu naczyniaków krwionośnych u dzieci PL244294B1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL442316A PL244294B1 (pl) 2022-09-20 2022-09-20 Kompozycja farmaceutyczna do stosowania miejscowego oraz jej zastosowanie w leczeniu naczyniaków krwionośnych u dzieci
PCT/PL2023/050078 WO2024063661A1 (en) 2022-09-20 2023-09-20 A pharmaceutical composition for topical application and use thereof in the treatment of hemangiomas in children
EP23818563.1A EP4590288A1 (en) 2022-09-20 2023-09-20 A pharmaceutical composition for topical application and use thereof in the treatment of hemangiomas in children

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL442316A PL244294B1 (pl) 2022-09-20 2022-09-20 Kompozycja farmaceutyczna do stosowania miejscowego oraz jej zastosowanie w leczeniu naczyniaków krwionośnych u dzieci

Publications (2)

Publication Number Publication Date
PL442316A1 true PL442316A1 (pl) 2023-09-11
PL244294B1 PL244294B1 (pl) 2024-01-03

Family

ID=88016760

Family Applications (1)

Application Number Title Priority Date Filing Date
PL442316A PL244294B1 (pl) 2022-09-20 2022-09-20 Kompozycja farmaceutyczna do stosowania miejscowego oraz jej zastosowanie w leczeniu naczyniaków krwionośnych u dzieci

Country Status (3)

Country Link
EP (1) EP4590288A1 (pl)
PL (1) PL244294B1 (pl)
WO (1) WO2024063661A1 (pl)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1040629B (en) * 1998-12-23 2005-01-28 Idea Ag Improved formulations for local non-diffusive administration in vivo
MX2008011236A (es) * 2006-03-01 2009-02-10 Tristrata Inc Composicion y metodo para tratamiento topico de trastornos dermatologicos que responden a alquitran.
EP2050441A1 (en) * 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
US8633181B2 (en) * 2009-04-09 2014-01-21 Rutgers, The State University Of New Jersey Treatment of cutaneous hemangioma
US11458199B2 (en) * 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations

Also Published As

Publication number Publication date
WO2024063661A1 (en) 2024-03-28
EP4590288A1 (en) 2025-07-30
PL244294B1 (pl) 2024-01-03

Similar Documents

Publication Publication Date Title
López Management of genitourinary syndrome of menopause in breast cancer survivors: An update
CO5700791A2 (es) Metodos para tratar enfermedades relacionadas con interleukin-6
Chen et al. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose–response study
Millot et al. Growth deceleration in children treated with imatinib for chronic myeloid leukaemia
Pu et al. Topical anesthetic agents for premature ejaculation: a systematic review and meta-analysis
CO5261535A1 (es) Combinacion farmaceutica util para el tratamiento de movilidad gastrointestinal alterada, sensibilidad de secrecion, o desordenes abdominales
Francavilla et al. Dysmenorrhea: epidemiology, causes and current state of the art for treatment
AR031822A1 (es) Composiciones farmaceuticas que contienen un inhibidor de cox-ii y un relajante muscular.
HRP20100014T1 (hr) Uporaba il-23 i il-17 antagonista u liječenju autoimune očne upalne bolesti
Bernardi et al. Effect of pilocarpine mouthwash on salivary flow
Safarinejad et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women
AR008293A1 (es) Composicion que comprende una cantidad antihistaminica para el tratamiento de las respuestas alergicas de las vias respiratorias superiores
HRP20130203T1 (hr) Postupak za lijeäśenje sindroma iritabilnog crijeva zbog prevladavajuä†eg zatvora
Khan et al. Tramadol use in premature ejaculation: daily versus sporadic treatment
Reid Premenstrual dysphoric disorder (formerly premenstrual syndrome)
EA200500306A1 (ru) Применение соединений антагонистов кальцитонин ген-связанного пептида (cgrp) для лечения псориаза
Becker et al. Prevention and treatment of neuraxial morphine-induced pruritus: a scoping review
Agrawal et al. Randomized controlled pilot trial of nifedipine as oral therapy vs topical application in the treatment of fissure-in-ano
Generini et al. Estrogens and neuropeptides in Raynaud's phenomenon
Saco et al. Prurigo nodularis: Picking the right treatment.
PL442316A1 (pl) Kompozycja farmaceutyczna do stosowania miejscowego oraz jej zastosowanie w leczeniu naczyniaków krwionośnych u dzieci
MXPA05012705A (es) Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
Kafaei-Atrian et al. The effect of acupressure at third liver point on the anxiety level in patients with primary dysmenorrhea
Ortner et al. Dose response of tramadol and its combination with paracetamol in UVB induced hyperalgesia
Ambach et al. Low‐dose combination therapy of severe digital ulcers in diffuse progressive systemic sclerosis with the endothelin‐1 receptor antagonist bosentan and the phosphodiesterase V inhibitor sildenafil